A Study to Optimize Subretinal Surgical Delivery and to Evaluate Safety and Activity of Opregen in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration (GAlette); Adaptive Optics (AO) Retinal Imaging Substudy in Association With Study GR44251
An Optimised GA Interventional Trial (Opti-GAIN) to Test if Treatment With CTx001 is Safe and Works for People With Geographic Atrophy (GA)
A Non-Interventional Study Observing Short-Term Progression in Geographic Atrophy (GA)
Microcurrent Stimulation Therapy for Intermediate to Advanced Nonexudative Age-related Macular Degeneration
Interested in new trials?
Get alerts for new trials in your area by subscribing now
A Study to Investigate Efficacy and Safety of FWY003 Compared With Placebo in Participants With Geographic Atrophy Secondary to Age-related Macular Degeneration
A Study of the Safety and Tolerability of ASP7317 in Senior Adults Who Are Losing Their Clear, Sharp Central Vision Due to Geographic Atrophy Secondary to Dry Age-related Macular Degeneration
A Phase 1/2 Study of the Safety and Efficacy of BRX011 Oral Administration Once Daily in Subjects With Geographic Atrophy Secondary to Age-Related Macular Degeneration
A Phase 1/2 Study to Evaluate the Safety and Efficacy of Intravitreal Administration of BS01 in Patients With Geographic Atrophy Secondary to Dry AMD
Autologous Transplantation of Induced Pluripotent Stem Cell-Derived Retinal Pigment Epithelium for Geographic Atrophy Associated With Age-Related Macular Degeneration
A Phase 2 Efficacy and Safety Study of GAL-101, 2% Ophthalmic Solution in Non-foveal Geographic Atrophy Secondary to Non-neovascular AMD
A Long-term Extension Study of JNJ-81201887 (AAVCAGsCD59) Parent Studies in Participants With Geographic Atrophy (GA) Secondary to Age-related Macular Degeneration (AMD)
What are geographic atrophy clinical trials?
Geographic atrophy clinical trials test ways to slow the loss of retinal cells, most often by calming an overactive part of the immune system called the complement pathway. Some trials study people in the earlier stages of the disease to see whether starting treatment sooner preserves more vision over time.
Why are clinical trials important for geographic atrophy research?
Until 2023, there was no approved treatment that targeted geographic atrophy directly, only supplements aimed at slowing progression toward it. The two treatments approved that year target the same immune pathway from slightly different angles, and neither restores vision already lost. Ongoing trials are how researchers are working toward earlier intervention and, eventually, real vision recovery.
Who can participate in geographic atrophy clinical trials?
Eligibility usually depends on how much of the retina is affected and which eye or eyes have geographic atrophy, since lesion size and location shape what a study can measure. Some trials focus on people who are newly diagnosed, while others look for those whose atrophy has continued to grow despite treatment. Eligibility always varies by study.
What types of geographic atrophy clinical trials are there?
Trials generally fall into a few groups. Some test complement inhibitor injections similar to the two already approved, others test entirely different mechanisms aimed at protecting retinal cells directly, and some are gene therapy approaches designed to reduce how often injections are needed. A smaller group focuses on better ways to detect and measure the disease earlier.
Is geographic atrophy the same as macular degeneration?
Geographic atrophy is a specific, advanced stage of macular degeneration, specifically the dry form. Not everyone with macular degeneration develops geographic atrophy, and the wet form of macular degeneration is a different process involving abnormal blood vessel growth rather than gradual cell loss.
Can geographic atrophy be confused with other eye conditions?
Yes, especially early on. Vision changes can overlap with diabetic retinopathy or glaucoma, particularly in older adults who may have more than one eye condition at once. A dilated eye exam and retinal imaging are what actually distinguish between them.
Is it safe to participate in geographic atrophy clinical trials?
Every study is reviewed by an independent ethics board before it can enroll anyone, and the specific risks, since most current treatments involve regular eye injections, are explained to you during informed consent, before you agree to anything.
Worried about the risks of participating in a clinical trial? Delve into our comprehensive guide to gain insights into the potential outcomes of participating. Learn about potential risks, benefits, and safety considerations to make an informed decision about your participation in a clinical trial.
Are geographic atrophy clinical trials paid?
Some studies offer compensation for time and travel, and study related care is typically provided at no cost to participants. Compensation varies by trial and is always described during the informed consent process before you agree to anything.
Curious whether clinical trials pay participants? Here's how compensation actually works.